|
End-of-day quote
Taiwan S.E.
2026-11-06
|
5-day change | 1st Jan Change | ||
| 21.00 TWD | -4.55% |
|
-14.63% | -20.45% |
Company Valuation: Formosa Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Market Cap 1 | 3,390 | 5,921 | 6,700 | 5,654 | 3,986 |
| Change | - | 74.66% | 13.17% | -15.62% | -29.51% |
| Enterprise Value (EV) 1 | 3,184 | 5,507 | 5,514 | 4,034 | 2,571 |
| Change | - | 72.94% | 0.13% | -26.84% | -36.27% |
| P/E | -7.91x | -13.6x | -19.3x | -26.2x | -47.7x |
| PBR | 8.63x | 12x | 5.88x | 3.65x | 2.74x |
| PEG | -0.2x | 1.2x | 0.6x | 0.6x | 0.8x |
| Capitalization / Revenue | 118,824,390x | 4,502,474,076x | 214,949,246x | 39,440,893x | 419,778,073x |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -9.22x | -16.1x | -22.3x | -28.8x | -20x |
| EV / EBIT | -8.38x | -14.6x | -19.5x | -23x | -15.1x |
| EV / FCF | -12.5x | -30.5x | 566x | -36.8x | -20.8x |
| FCF Yield | -8.02% | -3.27% | 0.18% | -2.72% | -4.81% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -4.334 | -3.822 | -2.595 | -1.43 | -0.5535 |
| Distribution rate | - | - | - | - | - |
| Net sales | 28.53 | 1.315 | 31.17 | 143.4 | 9.495 |
| EBITDA 1 | -345.4 | -341.2 | -247.5 | -140 | -128.4 |
| EBIT 1 | -380 | -377.3 | -283 | -175.6 | -170.6 |
| Net income 1 | -400.9 | -401.9 | -322 | -201 | -83.56 |
| Net Debt 1 | -205.7 | -414 | -1,186 | -1,620 | -1,415 |
| Reference price 2 | 34.30 | 52.10 | 49.95 | 37.45 | 26.40 |
| Nbr of stocks (in thousands) | 98,832 | 113,642 | 134,142 | 150,977 | 150,977 |
| Announcement Date | 3/16/22 | 3/21/23 | 2/26/24 | 3/13/25 | 3/12/26 |
1TWD in Million2TWD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 96.7M | |
| 39.62x | 13.42x | 28.51x | 0.5% | 1,206B | |
| 40.43x | 6.79x | 19.09x | 1.93% | 665B | |
| 37.52x | 8.51x | 17.57x | 2.38% | 515B | |
| 20.98x | 5.12x | 12.74x | 2.57% | 381B | |
| 97.18x | 5.94x | 25.33x | 2.32% | 362B | |
| 23.18x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.46x | 4.89x | 13.77x | 1.79% | 289B | |
| 23.75x | 7.3x | 13.55x | 2.19% | 249B | |
| -39.18x | 7.28x | 45.82x | 1.98% | 207B | |
| Average | 29.77x | 7.24x | 21.19x | 2.04% | 417.98B | |
| Weighted average by Cap. | 35.67x | 8.55x | 21.86x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 6838 Stock
- Valuation Formosa Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
